Acknowledgement
Supported by : Korea Health Industry Development Institute, National Research Foundation of Korea (NRF), Chonnam National University Hospital
References
- Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-35. https://doi.org/10.1056/NEJMoa1002358
- Zellweger MJ, Kaiser C, Jeger R, Brunner-La Rocca HP, Buser P, Bader F, et al. Coronary artery disease progression late after successful stent implantation. J Am Coll Cardiol 2012;59:793-9. https://doi.org/10.1016/j.jacc.2011.11.024
- Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6. https://doi.org/10.1161/hc0502.104278
- Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-11. https://doi.org/10.1016/S0735-1097(03)01044-1
- Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, et al. Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2013;81:959-67. https://doi.org/10.1002/ccd.24542
- Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 2014;52:1447-56.
- Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-9. https://doi.org/10.1016/j.tem.2007.11.001
- Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982;295:299-303. https://doi.org/10.1038/295299a0
- Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9. https://doi.org/10.1373/clinchem.2005.060038
- Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 2016;102:127-32. https://doi.org/10.1136/heartjnl-2015-308183
- Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol 2013;25:771-8. https://doi.org/10.1111/jne.12052
- Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94. https://doi.org/10.1093/eurheartj/ehp098
- CLSI. Procedures for the Handling and Processing of Blood Specimen for Common Laboratory Tests; 4th ed. H18-A4. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-98. https://doi.org/10.1016/j.jacc.2012.08.001
- Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77. https://doi.org/10.1093/eurheartj/ehx393
- Manginas A, Gatzov P, Chasikidis C, Voudris V, Pavlides G, Cokkinos DV. Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method. Am J Cardiol 1999;83: 1562-5. https://doi.org/10.1016/S0002-9149(99)00149-6
- Myler RK, Shaw RE, Stertzer SH, Hecht HS, Ryan C, Rosenblum J, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19:1641-52. https://doi.org/10.1016/0735-1097(92)90631-V
- Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
- Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8. https://doi.org/10.1016/j.jacc.2009.01.076
- Slagman A, Searle J, Muller C, Mockel M. Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction. Clin Chem 2015; 61:1273-82. https://doi.org/10.1373/clinchem.2015.240580
- von Haehling S, Papassotiriou J, Morgenthaler NG, Hartmann O, Doehner W, Stellos K, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol 2012;162:27-32. https://doi.org/10.1016/j.ijcard.2011.12.105
- Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007;115:2103-10. https://doi.org/10.1161/CIRCULATIONAHA.106.685503
- Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008;14:739-45. https://doi.org/10.1016/j.cardfail.2008.07.231
- Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011;76:563-6. https://doi.org/10.1212/WNL.0b013e31820b75e6
- Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009;66:799-808. https://doi.org/10.1002/ana.21783
- Jarai R, Mahla E, Perkmann T, Jarai R, Archan S, Tentzeris I, et al. Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery. Am J Cardiol 2011;108: 1188-95. https://doi.org/10.1016/j.amjcard.2011.06.024
- Geri G, Dumas F, Chenevier-Gobeaux C, Bougle A, Daviaud F, Morichau-Beauchant T, et al. Is copeptin level associated with 1-year mortality after out-of-hospital cardiac arrest? Insights from the Paris registry*. Crit Care Med 2015;43:422-9. https://doi.org/10.1097/CCM.0000000000000716
- Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65: 1454-71. https://doi.org/10.1016/j.jacc.2015.02.032
- McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 2010;362:228-38. https://doi.org/10.1056/NEJMcp0909392
Cited by
- Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown? vol.104, pp.11, 2019, https://doi.org/10.1210/jc.2019-01049
- Early myocardial injury biomarkers in diabetic hyperlipidemic rats: Impact of 10-dehydrogingerdione and vitamin D3 vol.245, pp.15, 2018, https://doi.org/10.1177/1535370220943124
- Cardiac Rehabilitation with Targeted Intensity Improves Cardiopulmonary Functions Accompanying with Reduced Copeptin Level in Patients with Coronary Artery Disease vol.14, pp.2, 2018, https://doi.org/10.1007/s12265-020-10055-y